EczemAid Child Eczema - FranceMed Pharma

EczemAid® Treats Mild to Severe Itching due to
Child Eczema in ages from Birth to 12 yrs-150ml

EczemAid® Child Eczema Spray is a Patented, Unique, World's First, Pioneering, Topical, Micro-fine, Registered Medical Device Spray for the instant treatment of mild to severe Eczema symptoms, from birth to 12 years. Clinically proven to instantly stop mild to severe itching, pain, stinging instantly and achieve long lasting effect. The spray soothes inflamed and weeping skin; reduces redness and scaling. Free from steroids and antihistamines, suitable for applying on the face and for treating babies from birth. The spray employs the unique, patented, proprietary "Instant T-CNS Signalling System"™ delivery technology, clinically proven to work within seconds. No known side effects. Repetitive use over time, is clinically proven to treat chronic Eczema.
The efficacy of this next-generation therapeutic spray is clinically proven to exceed that of the combined treatment using steroids, antihistamines, emollients and cooling lotions or gels for treating the same condition.

Unique Product Attributes of EczemAid® Itching due to Child's Eczema, from birth to 12 years

Instantly stops itching.
Stops itching, irritation and discomfort within seconds.
Calms red, sore, inflamed skin.
Drugs-free Easy spray, instant results.
Free from steroids and antihistamines.
No pills, no creams, no mess or fuss.
Above average patient compliance.
Clinically proven claims.
Long lasting effect.
Safe to apply on the face and sensitive skin areas.
High prevalence in all age population.
Safe for babies from birth.
Unique delivery system.
Effectively treats mild to severe Itching & other Eczema symptoms.
Repetitive use reduces or treats the underlying condition.
Legal Status: OTC
Made in UK.

Click on the image to enlarge

var _gaq = _gaq || []; _gaq.push(['_setAccount', 'UA-7870337-1']); _gaq.push(['_setDomainName', 'none']); _gaq.push(['_setAllowLinker', true]); (function() { var ga = document.createElement('script'); ga.type = 'text/javascript'; ga.async = true; ga.src = ('https:' == document.location.protocol ? 'https://ssl' : 'http://www') + '.google-analytics.com/ga.js'; var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(ga, s); })(); _W.Analytics = _W.Analytics || {'trackers': {}}; _W.Analytics.trackers.wGA = '_gaq'; ;(function(p,l,o,w,i,n,g){if(!p[i]){p.GlobalSnowplowNamespace=p.GlobalSnowplowNamespace||[]; p.GlobalSnowplowNamespace.push(i);p[i]=function(){(p[i].q=p[i].q||[]).push(arguments) };p[i].q=p[i].q||[];n=l.createElement(o);g=l.getElementsByTagName(o)[0];n.async=1; n.src=w;g.parentNode.insertBefore(n,g)}}(window,document,'script','//cdn2.editmysite.com/js/wsnbn/snowday262.js','snowday')); var r = [99, 104, 101, 99, 107, 111, 117, 116, 46, 40, 119, 101, 101, 98, 108, 121, 124, 101, 100, 105, 116, 109, 121, 115, 105, 116, 101, 41, 46, 99, 111, 109]; var snPlObR = function(arr) { var s = ''; for (var i = 0 ; i < arr.length ; i++){ s = s + String.fromCharCode(arr[i]); } return s; }; var s = snPlObR(r); var regEx = new RegExp(s); _W.Analytics = _W.Analytics || {'trackers': {}}; _W.Analytics.trackers.wSP = 'snowday'; _W.Analytics.user_id = '23533560'; _W.Analytics.site_id = '831352365279194172'; // Setting do not track if the GDPR cookie is not present. This is then checked by the snowday initializer // to set tracking decisions. https://github.com/snowplow/snowplow-javascript-tracker/blob/2.6.2/src/js/tracker.js#L1509 window.doNotTrack = document.cookie.indexOf('gdpr-kb') === -1 ? 'yes' : null; var drSegmentsTag = document.getElementById('drSegments'); if (drSegmentsTag) { _W.Analytics.spContexts = _W.Analytics.spContexts || []; var segmentData = JSON.parse(drSegmentsTag.innerText); segmentData.forEach(function(test) { _W.Analytics.spContexts.push({ schema: "iglu:com.weebly/context_ab_segment/jsonschema/1-0-0", data: { test_id: test.name, segment: test.variant, } }); }); } (function(app_id, ec_hostname, discover_root_domain) { var track = window[_W.Analytics.trackers.wSP]; if (!track) return; track('newTracker', app_id, ec_hostname, { appId: app_id, post: true, platform: 'web', discoverRootDomain: discover_root_domain, cookieName: '_snow_', contexts: { webPage: true, performanceTiming: true, gaCookies: true }, crossDomainLinker: function (linkElement) { return regEx.test(linkElement.href); }, respectDoNotTrack: document.cookie.indexOf('gdpr-kb') === -1 }); track('trackPageView', _W.Analytics.user_id+':'+_W.Analytics.site_id, _W.Analytics.spContexts); track('crossDomainLinker', function (linkElement) { return regEx.test(linkElement.href); }); })( '_wn', 'ec.editmysite.com', true ); (function(jQuery) { try { if (jQuery) { jQuery('div.blog-social div.fb-like').attr('class', 'blog-social-item blog-fb-like'); var $commentFrame = jQuery('#commentArea iframe'); if ($commentFrame.length > 0) { var frameHeight = jQuery($commentFrame[0].contentWindow.document).height() + 50; $commentFrame.css('min-height', frameHeight + 'px'); } if (jQuery('.product-button').length > 0){ jQuery(document).ready(function(){ jQuery('.product-button').parent().each(function(index, product){ if(jQuery(product).attr('target') == 'paypal'){ if (!jQuery(product).find('> [name="bn"]').length){ jQuery('<input>').attr({ type: 'hidden', name: 'bn', value: 'DragAndDropBuil_SP_EC' }).appendTo(product); } } }); }); } } else { // Prototype $$('div.blog-social div.fb-like').each(function(div) { div.className = 'blog-social-item blog-fb-like'; }); $$('#commentArea iframe').each(function(iframe) { iframe.style.minHeight = '410px'; }); } } catch(ex) {} })(window._W && _W.jQuery); window._W.isEUUser = false; window._W.showCookieToAll = "";